Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 14/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17732239 | 0.89 | SIGMAR1 (0.52) | RENSIGMAR1 | |
| SCHEMBL14114916 | 0.89 | ALOX15 (0.55) | RENSIGMAR1ALOX15ALOX12 | |
| SCHEMBL2738334 | 0.89 | ALOX15 (0.55) | RENSIGMAR1ALOX15ALOX12 | |
| SCHEMBL16930132 | 0.86 | REN (0.54) | REN | |
| SCHEMBL18425645 | 0.86 | REN (0.54) | REN | |
| SCHEMBL29840539 | 0.86 | REN (0.54) | REN | |
| SCHEMBL16973682 | 0.85 | ALOX15 (0.64) | ALOX15ALOX12 | |
| SCHEMBL22899046 | 0.85 | ALOX15 (0.55) | RENALOX15ALOX12 | |
| SCHEMBL16973499 | 0.85 | REN (0.40) | REN | |
| SCHEMBL16973619 | 0.85 | PNMT (0.42) | RENALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490987-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION | Newave Pharmaceutical Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018041873-A1 | PROCESS FOR THE PREPARATION OF (6S)-6-ISOPROPYL-10-METHOXY-9-(3-METHOXYPROPOXY)-2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018022282-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION | NEWAVE PHARMACEUTICAL INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| EP-3143020-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017016960-A1 | PROCESS FOR THE PREPARATION OF (6S)-6-ALKYL-10-ALKOXY-9-(SUBSTITUTED ALKOXY)-2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID ANALOGUES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017016921-A1 | NEW CRYSTALLINE FORMS OF (6S)-10-METHOXY-6-ISOPROPYL-9-(3-METHOXYPROPOXY)-2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-02 | — | — | WO | disclosed |
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015173164-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | disclosed |